Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Antibiotic exposure not a risk factor for coeliac disease in children

02 Jul 2019

Prenatal or postnatal antibiotic exposure does not contribute to an increased risk of developing coeliac disease (CD) in children, according to a recent study.

Researchers conducted a systematic review of studies in which either women during any trimester of pregnancy or infants and young children underwent intravenous or oral antibiotic treatment if the exposure preceded the CD diagnosis. A total of six studies were included.

All studies evaluated the exposure to any antibiotics, while specific types of antibiotics such as penicillins, cephalosporins and macrolides were considered only in three studies. One study provided specific data about early (≤17 weeks of pregnancy) and late (pregnancy week 18 until delivery) pregnancy. For postnatal exposure, the age at antibiotic exposure ranged from birth to 4 years.

In the large Norwegian and Swedish cohorts that evaluated prenatal antibiotic exposure, no association with the risk of CD was found (adjusted odds ratio [OR], 1.16, 95 percent CI, 0.94–1.43 and adjusted hazards ratio [HR], 1.33, 0.69–2.56, respectively).

On the other hand, the results were contradictory in three studies that explored the association between postnatal antibiotic exposure and the risk of CD, with only the Italian cohort study reporting a significant positive association (adjusted incidence rate ratio, 1.24, 1.07–1.43).

Finally, a large multicentre cohort study that evaluated the association between postnatal antibiotic exposure and CD autoimmunity in human leukocyte antigen (HLA)-positive subjects showed null results.

Additional investigation is still needed to elucidate the effects of antibiotic use or underlying infections, or both, on the development of CD/CD autoimmunity, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).